Pantothenic Acid for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Pantothenic Acid for Health & Longevity

Created on 07/08/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A widespread B vitamin that rarely runs short, so extra amounts do little for well-nourished people. Its clearest gains are form-specific: pantethine modestly lowers cholesterol and blood fats, and a topical form aids skin and wound repair. Very well tolerated, with high doses mainly causing digestive upset. Longevity impact stays uncertain. (Full Review)

Protocol

Lipid Lowering
Pantethine 600–900 mg/day
The form used in cholesterol trials, not plain B5
General Sufficiency
5 mg/day (Adequate Intake)
Met by diet or a standard B-complex (5–10 mg)
Dosing
Divided doses with meals
Split into 2–3 daily doses to reduce digestive upset
Time to effect
Cholesterol & Triglycerides
8–16 weeks
Pantethine; several months before judging response
Facial Acne
12 weeks
High-dose oral form

Benefits

Contraindications
  • Bleeding disorders (e.g., hemophilia)
  • Pregnancy or breastfeeding (multi-gram doses)
    •
Key Interactions
  • Statins (atorvastatin, rosuvastatin)
  • Anticoagulants/antiplatelets (warfarin, aspirin, clopidogrel)
  • High-dose biotin products
  • Topical retinoids (isotretinoin, adapalene)
  • Lipid-lowering supplements (red yeast rice, plant sterols, berberine, soluble fiber, omega-3)
    •

Risk & Side Effects

  • High: Digestive upset at high doses
    •
  • Medium:
  • Low: Interference with certain blood tests; pantethine mildly reduces platelet aggregation
    •
  • Speculative: Isolated eosinophilic fluid around the heart and lungs; theoretical adrenal or hormonal over-stimulation
    •

Monitoring

Marker Target Why
LDL cholesterol (LDL-C) < 100 mg/dL Primary target when pantethine is used for lipids
Triglycerides < 90 mg/dL Pantethine's largest reported effect
HDL cholesterol (HDL-C) > 50 mg/dL (women), > 45 mg/dL (men) Tracks the modest HDL rise seen with pantethine
Apolipoprotein B (ApoB) < 80 mg/dL Counts atherogenic particles directly
High-sensitivity C-reactive protein (hs-CRP) < 1.0 mg/L Systemic inflammation and cardiovascular risk context
Fasting glucose 70–90 mg/dL Cardiometabolic risk context in the dyslipidemia population

Cadence: Baseline lipid panel before starting; recheck at 8–12 weeks, then every 6–12 months during continued use

Qualitative Assessment

  • Energy and general well-being (expected to change only if a true deficiency is corrected)
  • Skin condition and acne lesion counts, when acne is the target
  • Digestive tolerance — loose stools or cramping signal the dose is too high
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.